**Nulibry® (fosdenopterin)**  
**Effective 11/01/2021**

<table>
<thead>
<tr>
<th>Plan</th>
<th>☒ MassHealth</th>
<th>☐ Commercial/Exchange</th>
<th>Program Type</th>
<th>☒ Prior Authorization</th>
<th>☐ Quantity Limit</th>
<th>☐ Step Therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Benefit</td>
<td>☐ Pharmacy Benefit</td>
<td>☒ Medical Benefit (NLX)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Specialty Limitations</td>
<td>N/A</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Contact Information</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Specialty Medications</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All Plans</td>
<td>Phone: 866-814-5506</td>
<td>Fax: 866-249-6155</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-Specialty Medications</td>
<td>MassHealth</td>
<td>Phone: 877-433-7643</td>
<td>Fax: 866-255-7569</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Commercial</td>
<td>Phone: 800-294-5979</td>
<td>Fax: 888-836-0730</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Exchange</td>
<td>Phone: 855-582-2022</td>
<td>Fax: 855-245-2134</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medical Specialty Medications (NLX)</td>
<td>All Plans</td>
<td>Phone: 844-345-2803</td>
<td>Fax: 844-851-0882</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Exceptions</td>
<td>N/A</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Overview**
Nulibry is cyclic pyranopterin monophosphate (cPMP) indicated to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A.

**Coverage Guidelines**
Authorization may be reviewed for members new to AllWays Health Partners who are currently receiving treatment with Nulibry excluding when the product is obtained as samples or via manufacturer’s patient assistance programs.

**OR**
Authorization may be granted for members when ALL the following criteria are met, and documentation is provided:
1. Appropriate diagnosis of molybdenum cofactor deficiency (MoCD) Type A confirmed by genetic testing
2. Prescriber is a specialist in genetic or metabolic diseases or consult is provided
3. Appropriate dosing
4. Member’s current weight.

**Continuation of Therapy**
Reauthorization will be granted if member meets all of the following criteria:
1. Improved change in molybdenum cofactor deficiency biomarkers
2. Improved growth parameters

**Limitations**
1. Initial approvals will be granted for 3 months
2. Reauthorizations will be granted for 12 months

References
5. ClinicalTrials.gov. Safety & efficacy study of ORGN001 (formerly ALXN1101) in pediatric patients with MoCD type A currently treated with rCPMP. Available at: https://clinicaltrials.gov/ct2/show/NCT02047461.

Review History
09/22/2021 – Reviewed and Created for Sept P&T. Effective 11/01/2021

Disclaimer
AllWays Health Partners complies with applicable federal civil rights laws and does not discriminate or exclude people on the basis of race, color, national origin, age, disability, or sex.